Industry News

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered public offering of an aggregate of approximately 28.6 million shares of common stock at a price to the public of $0.70 per share. Investors will also receive warrants to purchase up to an aggregate of approximately 28.6 million shares of common stock with an exercise price of $0.70 per share."/>
CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
Zimmer Biomet Holdings, Inc. has completed its offer to purchase all outstanding shares of the common stock of LDR Holding Corporation, the company said. Goldman, Sachs& Co. acted as financial advisor to Zimmer Biomet and White& Case LLP acted as legal advisor to Zimmer Biomet in connection with the transaction. At the time of expiration of the offer, 24,278,729 shares of LDR common stock had been validly tendered, representing approximately 82.7 percent of outstanding shares."/>
Zimmer Biomet completes tender offer for outstanding shares of LDR
Boston Herald The Ticker column [Boston Herald]
Glaukos Corporation stated on Thursday that Richard L Harrison intends to step down as its chief financial officer in 2017 in order to dedicate more time to family and personal interests. Since January 2008, Harrison has served as chief financial officer at the company. In conjunction with the planned retirement, Harrison will remain in his current role until a successor is named and he has agreed to assist with an orderly transition."/>
Glaukos discloses planned departure of CFO Richard L Harrison
ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it has retained Mackie Research Capital Corporation to provide market maintenance services for the company in compliance with regulatory guidelines. Mackie will trade shares of ProMIS on the TSX for the purposes of maintaining a reasonable market and improving the liquidity of ProMIS's shares."/>
ProMIS Neurosciences Announces Retention of Mackie Research Capital Corporation as Market Maintenance Service Provider
Emergent BioSolutions Inc. today announced that its Board of Directors has authorized the company’ s management to implement a stock repurchase program for up to $50 million of the company's common stock from time to time on the open market or in privately negotiated transactions.. “The company’ s board and management believe that Emergent’ s stock price does not reflect what we consider are the fundamentals of our company’ s value,” said Daniel J...."/>
Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
HealthSouth Corporation and Novant Health, Inc., have formed a joint venture to file a Certificate of Need application to build a 68- bed, freestanding inpatient rehabilitation hospital in Winston-Salem, North Carolina. The Certificate of Need application requests that the rehabilitation unit currently located at the Novant Health Rehabilitation Center at 3333 Silas Creek Parkway in Winston-Salem be..."/>
Healthsouth And Novant Health Announce Plans To Build An Inpatient Rehabilitation Hospital
Celgene International Srl revealed on Friday the receipt of the European Commission's approval for REVLIMID for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, a rare sub-type of aggressive non-Hodgkin's lymphoma that causes tumours known as lymphomas. The EC approval for the use of company's REVLIMID in adult patients with relapsed/refractory MCL follows the encouraging opinion issued by the Committee for Medicinal Products for..."/>
Celgene International Sàrl awarded EC's approval for REVLIMID (lenalidomide) for relapsed or refractory mantle cell lymphoma
CytRx Corporation stated on Thursday that it plans to launch its registered public offering of its common stock and one year warrants to purchase common stock. Subject to market and other conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Rodman& Renshaw, a unit of HC Wainwright& Co, is acting as exclusive placement agent for the offering."/>
CytRx Corporation plans to issue common stock and warrants in public offering
Cardiome Pharma Corp disclosed on Thursday the receipt of pricing approval and national reimbursement for both ESMOCARD and ESMOCARD LYO in Italy. The company said ESMOCARD is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a..."/>
Cardiome Pharma Corp secures pricing approval and reimbursement in Italy for ESMOCARD and ESMOCARD LYO
CellaVision AB: Interim Report January-June 2016
Angle plc. Notification of Preliminary Results and Webcast. ANGLE plc, the specialist medtech company, will be releasing its preliminary results for the year ended 30 April 2016 on Thursday 28 July 2016.."/>
Angle PLC: Notice of Results
Juno Therapeutics RedoxTherapies to Continue to Pursue Development of Vipadenant. Vernalis plc notes the announcement by Juno Therapeutics, Inc. that RedoxTherapies, Inc. and Juno have entered into a share purchase agreement, pursuant to which Juno acquired the outstanding shares of RedoxTherapies."/>
Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics
ANGLE plc, the specialist medtech company, is pleased to announce that significant profile was achieved for ANGLE's Parsortix system at EACR 2016 held in Manchester 9 to 12 July 2016.. Importantly, performance of the system was referenced in two keynote presentations by independent investigators, Caroline Dive of Cancer Research UK Manchester Institute and Klaus Pantel of University Medical Centre Hamburg-Eppendorf respectively."/>
ANGLE plc ("the Company"): Parsortix Gaining Traction at Prestigious EACR Conference
Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union. BOUDRY, Switzerland---- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation today announced that the European Commission has approved REVLIMID ® for the treatment of adult..."/>
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Piramal Enterprises Ltd's healthcare business. The real estate investment business under Piramal Fund Management Pvt. Ltd and the mezzanine funding unit, known as Structured Investment Group, have been merged under the former."/>
Piramal restructures its financial services business [Mint, New Delhi]
EndyMed announced today that it had signed a distribution agreement in South Korea for its Newa Skin Care System home-use wrinkle reduction device. The distributor will sell the device together with the company's cosmetic products. The agreement is for two years, and is worth a minimum of $2.5 million, of which $900,000 will be in the first year."/>
BRIEF: EndyMed signs distribution agreement in S Korea [Globes, Tel Aviv, Israel]
Acadia Healthcare Company, Inc.' s closed acquisition of UK-based behavioral healthcare services provider Priory Group, the CMA said. The CMA, which is the United Kingdom's primary competition and consumer authority, said that the acquisition of Priory by Acadia will be referred for a Phase 2 investigation, unless Acadia and..."/>
UK Competition and Markets Authority Threatens Move to Phase 2 Probe of Acadia Healthcare/ Priory Tie-Up
GN Store Nord A/S, announced it had closed the acquisition July 1 and would pay $91 million up front with another $60 million contingent on Audigy's future earnings. Audigy said its 186 employees in Vancouver will not be affected by the sale."/>
Vancouver's Audigy sells for $151 million [The Columbian, Vancouver, Wash.]
CytRx Corporation concerning possible violations of federal securities laws. If you purchased shares of CytRx and want more information, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 419-3834, or by e-mail at There has been no class certification in this case."/>
SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of CytRx Corporation and Reminds Investors with Losses to Contact the Firm
Eagle Pharmaceuticals Inc. concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here to participate."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. and Reminds Investors With Losses to Contact the Firm

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials953 Articles
Information Technology898 Articles
Consumer Discretionary751 Articles
Health Care595 Articles
Industrials595 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at